Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis
Status:
Withdrawn
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of fasiglifam 50 mg once daily compared to placebo on glycemic
control as measured by glycosilated haemoglobin (HbA1c) over a 16-week treatment period in
participants with Type 2 Diabetes Mellitus (T2DM) and chronic kidney disease (CKD) stage 4 or
5 on dialysis.